Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the 1115 Waiver topic
No spam. Unsubscribe anytime.
San Francisco prepares to implement expanded Drug Medi‑Cal services under federal 1115 waiver
Summary
City health officials briefed the Health Commission on recent 1115 waiver amendments that add prenatal/postpartum coverage and a substance‑use organized delivery system to Medi‑Cal; staff said San Francisco will opt into the phase‑1 Bay Area implementation but warned of provider certification and startup financing challenges.
San Francisco public health officials told the Health Commission they are moving ahead with implementation of newly amended components of the federal Section 1115 Medicaid demonstration waiver that expand prenatal/postpartum coverage and add an organized delivery system for substance‑use disorder services.
Colleen Chella, a health department staffer, said the waiver amendments extend full‑scope Medi‑Cal prenatal and postpartum coverage above 109 percent of the federal poverty level and add a substance‑use disorder managed care framework to Drug Medi‑Cal. The current 1115 waiver is scheduled to expire October 30; Chella said these elements are expected to be carried into the waiver renewal.
Doctor Judith Martin, who led the department’s substance‑use update, told commissioners the state’s amendment to Drug Medi‑Cal was approved on August 13 and that Bay Area counties were selected for phase‑1 implementation. “We’re opting in,” Martin said, describing tasks ahead: drafting an implementation plan with timelines, negotiating realistic reimbursement rates with the state, and signing new contracts with community providers.
Commissioners pressed staff on how many San Francisco residents will be affected and whether the county has enough certified providers to meet the expanded benefit. Martin said the department is actively helping community‑based organizations apply for Drug Medi‑Cal certification, but noted those applications trigger a lengthy remediation process by the state. She listed practical constraints: there are no state start‑up incentives, certification requires increased accountability and recordkeeping, and low initial rates risk high staff turnover among providers.
Several commissioners raised financial concerns. One noted San Francisco already provides a broad array of substance‑use services and asked whether the new federal match will bring net new resources or simply shift costs and obligations. Martin said it is too early to quantify the net fiscal impact, though she expected an increase in federal match for services already billed through Drug Medi‑Cal and cautioned that general‑fund supported diversion programs may not be fully supplanted by the waiver.
Why it matters: the 1115 waiver amendment could expand access to evidence‑based substance‑use care in Medi‑Cal and create a steadier revenue stream for certified programs; at the same time, local officials warned that provider certification, staffing capacity and initial rate setting will determine whether that potential is realized.
What happens next: staff said they are writing implementation plans and rate proposals, and will return to the commission with further details as they negotiate contracts and support providers through certification.
